Duality Biotherapeutics, Inc. (HKG:9606)

Market Cap	18.87B
Revenue (ttm)	2.07B
Net Income (ttm)	-1.12B
Shares Out	88.04M
EPS (ttm)	-139.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,475
Average Volume	409,752
Open	212.20
Previous Close	209.00
Day's Range	207.20 - 215.00
52-Week Range	165.50 - 234.60
Beta	n/a
RSI	54.63
Earnings Date	n/a

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 170
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9606

Financial Performance

Financial numbers in CNY